CA2858315C - Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors - Google Patents

Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors Download PDF

Info

Publication number
CA2858315C
CA2858315C CA2858315A CA2858315A CA2858315C CA 2858315 C CA2858315 C CA 2858315C CA 2858315 A CA2858315 A CA 2858315A CA 2858315 A CA2858315 A CA 2858315A CA 2858315 C CA2858315 C CA 2858315C
Authority
CA
Canada
Prior art keywords
tumor
minicells
brain
composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858315A
Other languages
English (en)
French (fr)
Other versions
CA2858315A1 (en
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EnGeneIC Molecular Delivery Pty Ltd
Original Assignee
EnGeneIC Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnGeneIC Molecular Delivery Pty Ltd filed Critical EnGeneIC Molecular Delivery Pty Ltd
Publication of CA2858315A1 publication Critical patent/CA2858315A1/en
Application granted granted Critical
Publication of CA2858315C publication Critical patent/CA2858315C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2858315A 2011-12-13 2012-12-12 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors Active CA2858315C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569907P 2011-12-13 2011-12-13
US61/569,907 2011-12-13
PCT/IB2012/002950 WO2013088250A1 (en) 2011-12-13 2012-12-12 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Publications (2)

Publication Number Publication Date
CA2858315A1 CA2858315A1 (en) 2013-06-20
CA2858315C true CA2858315C (en) 2020-05-12

Family

ID=48611925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858315A Active CA2858315C (en) 2011-12-13 2012-12-12 Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

Country Status (23)

Country Link
US (3) US9844598B2 (cg-RX-API-DMAC7.html)
EP (1) EP2790668B1 (cg-RX-API-DMAC7.html)
JP (2) JP6522340B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140102294A (cg-RX-API-DMAC7.html)
CN (2) CN104114153A (cg-RX-API-DMAC7.html)
AU (2) AU2012351743B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858315C (cg-RX-API-DMAC7.html)
CY (1) CY1123824T1 (cg-RX-API-DMAC7.html)
DK (1) DK2790668T3 (cg-RX-API-DMAC7.html)
ES (1) ES2843402T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201930T1 (cg-RX-API-DMAC7.html)
HU (1) HUE052136T2 (cg-RX-API-DMAC7.html)
IL (1) IL233031B (cg-RX-API-DMAC7.html)
LT (1) LT2790668T (cg-RX-API-DMAC7.html)
MX (2) MX359410B (cg-RX-API-DMAC7.html)
PT (1) PT2790668T (cg-RX-API-DMAC7.html)
RS (1) RS61161B1 (cg-RX-API-DMAC7.html)
RU (1) RU2664698C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201601349XA (cg-RX-API-DMAC7.html)
SI (1) SI2790668T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000676T1 (cg-RX-API-DMAC7.html)
TW (1) TWI627966B (cg-RX-API-DMAC7.html)
WO (1) WO2013088250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007322A (es) * 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX355683B (es) 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
BRPI1015295A2 (pt) 2009-04-20 2016-05-31 Angiochem Inc traamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2.
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2843402T3 (es) 2011-12-13 2021-07-16 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CN105658233B (zh) * 2013-10-04 2020-09-04 安吉尼科分子传输公司 使用携带药物的、双特异性配体靶向的微细胞和干扰素-γ的联合肿瘤治疗
CA2955177A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US10328159B2 (en) 2014-10-03 2019-06-25 Engenic Molecular Delivery Pty Ltd. Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
DE102018220892A1 (de) * 2018-12-04 2020-06-04 Robert Bosch Gmbh Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs
PH12021551315A1 (en) * 2018-12-10 2022-05-16 Flagship Pioneering Innovations Vi Llc Achromosomal dynamic active systems
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
JP2022536982A (ja) * 2019-06-21 2022-08-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 癌およびその他の疾患の処置のためのα３β１インテグリンの標的化
CN111001014B (zh) * 2019-12-12 2022-04-22 四川大学华西医院 一种基于固定细菌做载体的抗肿瘤药物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0222340Y2 (cg-RX-API-DMAC7.html) 1986-11-18 1990-06-15
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6540980B1 (en) 1999-04-02 2003-04-01 Center For Molecular Medicine And Immunology Method of detecting endometriosis
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030203411A1 (en) * 2001-06-05 2003-10-30 Sabbadini Roger A. Methods of minicell-based delivery
CA2775218C (en) * 2001-10-15 2016-04-26 Engeneic Molecular Delivery Pty Ltd. Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
ATE461713T1 (de) 2002-05-29 2010-04-15 Immunomedics Inc Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
KR101115797B1 (ko) * 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CN101954095B (zh) * 2003-12-09 2013-03-13 基因分子传递股份有限公司 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞
RS54149B1 (sr) * 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd. Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US7837998B2 (en) * 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
MX2007002294A (es) * 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente.
WO2006099445A2 (en) 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
JP2009531324A (ja) * 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
PL2712618T3 (pl) * 2006-06-23 2017-07-31 Engeneic Molecular Delivery Pty Ltd. Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne
WO2008050255A2 (en) 2006-10-25 2008-05-02 Koninklijke Philips Electronics N. V. Contrast agents for detecting prostate cancer
SG10201507969PA (en) 2007-03-30 2015-10-29 Engeneic Molecular Delivery Pty Ltd Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
EP3020811A1 (en) * 2008-06-25 2016-05-18 Vaxiion Therapeutics, LLC Regulated genetic suicide mechanism compositions and methods
EP3059247B1 (en) * 2008-12-05 2017-09-20 Abraxis BioScience, LLC Sparc binding peptides and uses thereof
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
DK2675474T3 (en) * 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
ES2843402T3 (es) 2011-12-13 2021-07-16 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales
EP3826654A4 (en) 2018-07-23 2022-07-06 EnGeneIC Molecular Delivery Pty Ltd COMPOSITIONS COMPRISING MINICELLS OF BACTERIAL ORIGIN AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
IL233031B (en) 2019-12-31
WO2013088250A1 (en) 2013-06-20
KR102046042B1 (ko) 2019-11-18
RS61161B1 (sr) 2021-01-29
WO2013088250A4 (en) 2013-10-24
US9844598B2 (en) 2017-12-19
EP2790668A4 (en) 2015-07-15
KR20140102294A (ko) 2014-08-21
JP6594383B2 (ja) 2019-10-23
KR20190084349A (ko) 2019-07-16
MX2014006967A (es) 2014-12-05
CY1123824T1 (el) 2022-03-24
LT2790668T (lt) 2020-12-28
US10994014B2 (en) 2021-05-04
NZ626187A (en) 2016-06-24
HUE052136T2 (hu) 2021-04-28
MX385832B (es) 2025-03-18
JP6522340B2 (ja) 2019-05-29
SG11201403062YA (en) 2014-07-30
US11964021B2 (en) 2024-04-23
AU2012351743A1 (en) 2014-07-03
US20210213133A1 (en) 2021-07-15
MX359410B (es) 2018-09-27
AU2012351743B2 (en) 2017-07-06
TWI627966B (zh) 2018-07-01
PT2790668T (pt) 2020-11-10
SMT202000676T1 (it) 2021-01-05
ES2843402T3 (es) 2021-07-16
HRP20201930T1 (hr) 2021-02-05
JP2015500328A (ja) 2015-01-05
RU2014128338A (ru) 2016-02-10
US20130177499A1 (en) 2013-07-11
SG10201601349XA (en) 2016-03-30
IL233031A0 (en) 2014-07-31
EP2790668B1 (en) 2020-09-09
JP2018024678A (ja) 2018-02-15
SI2790668T1 (sl) 2021-01-29
AU2017239542A1 (en) 2017-10-26
RU2664698C2 (ru) 2018-08-21
EP2790668A1 (en) 2014-10-22
DK2790668T3 (da) 2020-11-23
CN109125286A (zh) 2019-01-04
CA2858315A1 (en) 2013-06-20
TW201330860A (zh) 2013-08-01
NZ709680A (en) 2017-03-31
CN104114153A (zh) 2014-10-22
AU2017239542B2 (en) 2019-04-04
HK1201473A1 (en) 2015-09-04
US20180043027A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
US11964021B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
KR102433719B1 (ko) 약물 로딩된, 이중특이성 리간드-표적화된 미니세포 및 인터페론 감마에 의한 복합 종양 치료
US20220202950A1 (en) Compositions comprising bacterially derived intact minicells for theranostic applications
López-Estévez et al. Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging
NZ709680B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
HK1201473B (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
NZ626187B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
BR112016007100B1 (pt) Uso de composição, composição e kit

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171204